We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Failure to fully investigate complaints or to properly qualify suppliers landed devicemaker Austco Marketing and Service a Form 483 after an FDA inspection at its Irving, Texas, facility.
An FDA inspection of an iRhythm Technologies facility in Irvine, Calif., resulted in a Form 483 to the firm for not establishing corrective and preventative actions, not submitting a medical device report (MDR), and other issues regarding the company’s cardiac monitoring system.
The FDA has issued separate warning letters to Olympus Medical Systems and its subsidiary Aizu Olympus for failure to report malfunctions of endoscopes and inadequate validations.
An FDA inspection of East Troy, Wis., implantable medical device manufacturer Cytophil showed unvalidated processes and inadequate testing, among other lapses.
Buffalo, N.Y.-based Pedia Parents was handed a Form 483 after a July inspection found the company lacked adequate procedures for supplier monitoring, design verifications and medical device reports (MDR), among other lapses.
The FDA sent a Warning Letter to RoyalVibe Health for unapproved ultrasound technology devices the company has not removed from the market and for continuing to market the products online.
The FDA has issued Florida-based test manufacturer Empowered Diagnostics a warning letter for distributing COVID-19 test kits without marketing approval, clearance, or authorization.
Reviewing the deficiencies cited in FDA’s Form 483s inspection reports to devicemakers, just five areas account for almost 25 percent of all the observations by agency investigators each year. Read More
An FDA inspection of Apneicare’s medical device facility in Columbus, Ohio, turned up several repeat observations, including problems with handling complaints, completing corrective action reports and updating product labeling. Read More
To clear up any confusion about what the FDA considers delaying, denying, limiting, or refusing a drug or device inspection, the agency released a draft guidance on Thursday.